Laksshman Sundaram

Laksshman Sundaram

Auto-generated profile, based on publicly available information

Laksshman Sundaram

Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2018 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
LSLaksshman Sundaram
Laksshman Sundaram
HGHong Gao
Hong Gao
SPSamskruthi Reddy Padigepati
Samskruthi Reddy Padigepati
JMJeremy F. McRae
Jeremy F. McRae
YLYanjun Li
Yanjun Li
KFKyle Kai-How Farh
Kyle Kai-How Farh

1 September 2021 in Cell
Verified
Journal Article
Closed access
ATAlexandro E. Trevino
Alexandro E. Trevino
FMFabian Müller
Fabian Müller
JAJimena Andersen
Jimena Andersen
LSLaksshman Sundaram
Laksshman Sundaram
AKArwa Kathiria
Arwa Kathiria
WGWilliam J. Greenleaf
William J. Greenleaf

2 June 2023 in Science
Verified
Journal Article
Closed access
HGHong Gao
Hong Gao
THTobias Hamp
Tobias Hamp
JEJeffrey Ede
Jeffrey Ede
JSJoshua G. Schraiber
Joshua G. Schraiber
JMJeremy McRae
Jeremy McRae
KFKyle Kai-How Farh
Kyle Kai-How Farh
Personalized genome sequencing has revealed millions of genetic differences between individuals, but our understanding of their clinical relevance remains largely incomplete. To systematically decipher the effects of human genetic variants, we obtained whole-genome sequencing data for 809 individuals from 233 primate species and identified 4.3 million common protein-altering variants with orthologs in humans. We show that these variants can be inferred to have nondeleterious effects in humans based on their presence at high allele frequencies in other primate populations. We use this resource to classify 6% of all possible human protein-altering variants as likely benign and impute the pathogenicity of the remaining 94% of variants with deep learning, achieving state-of-the-art accuracy for diagnosing pathogenic variants in patients with genetic diseases.

22 December 2022 in Cell
Verified
Journal Article
Closed access
MAMohamed Ameen
Mohamed Ameen
LSLaksshman Sundaram
Laksshman Sundaram
MSMengcheng Shen
Mengcheng Shen
ABAbhimanyu Banerjee
Abhimanyu Banerjee
SKSoumya Kundu
Soumya Kundu
AKAnshul Kundaje
Anshul Kundaje

6 September 2024 in Science
Verified
Journal Article
Closed access
LSLaksshman Sundaram
Laksshman Sundaram
AKArvind Kumar
Arvind Kumar
MZMatthew Zatzman
Matthew Zatzman
ASAdriana Salcedo
Adriana Salcedo
NRNeal Ravindra
Neal Ravindra
HSHui Shen
Hui Shen
To identify cancer-associated gene regulatory changes, we generated single-cell chromatin accessibility landscapes across eight tumor types as part of The Cancer Genome Atlas. Tumor chromatin accessibility is strongly influenced by copy number alterations that can be used to identify subclones, yet underlying cis-regulatory landscapes retain cancer type–specific features. Using organ-matched healthy tissues, we identified the “nearest healthy” cell types in diverse cancers, demonstrating that the chromatin signature of basal-like–subtype breast cancer is most similar to secretory-type luminal epithelial cells. Neural network models trained to learn regulatory programs in cancer revealed enrichment of model-prioritized somatic noncoding mutations near cancer-associated genes, suggesting that dispersed, nonrecurrent, noncoding mutations in cancer are functional. Overall, these data and interpretable gene regulatory models for cancer and healthy tissue provide a framework for understanding cancer-specific gene regulation.

12 May 2025 in Nature Genetics
Verified
Journal Article
Open access
KYKathryn E. Yost
Kathryn E. Yost
YZYanding Zhao
Yanding Zhao
KHKing L. Hung
King L. Hung
KZKaiyuan Zhu
Kaiyuan Zhu
DXDuo Xu
Duo Xu
HCHoward Y. Chang
Howard Y. Chang
Genome conformation underlies transcriptional regulation by distal enhancers, and genomic rearrangements in cancer can alter critical regulatory interactions. Here we profiled the three-dimensional genome architecture and enhancer connectome of 69 tumor samples spanning 15 primary human cancer types from The Cancer Genome Atlas. We discovered the following three archetypes of enhancer usage for over 100 oncogenes across human cancers: static, selective gain or dynamic rewiring. Integrative analyses revealed the enhancer landscape of noncancer cells in the tumor microenvironment for genes related to immune escape. Deep whole-genome sequencing and enhancer connectome mapping provided accurate detection and validation of diverse structural variants across cancer genomes and revealed distinct enhancer rewiring consequences from noncoding point mutations, genomic inversions, translocations and focal amplifications. Extrachromosomal DNA promoted more extensive enhancer rewiring among several types of focal amplification mechanisms. These results suggest a systematic approach to understanding genome topology in cancer etiology and therapy.